In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novelix Pharmaceuticals Inc.

Latest From Novelix Pharmaceuticals Inc.

Novelix Pharmaceuticals Inc.

For 15 years, its founders dreamed of starting a company to design new cancer drugs, but it wasn't until 2005 that they were able to lock up all the compounds they wanted. Novelix Pharmaceuticals now boasts a preclinical pipeline that's four candidates strong--all novel, proprietary, small molecules with innovative modes of action and favorable ADMET profiles.

Start-Up Previews (3/06)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, Cardiac Regeneration Start-Ups Look to Repair, not Replace, features profiles of Arteriocyte, Celladon, NanoCor Therapeutics and Theregen. Plus these Start-Up Across Health Care: Alder Biopharmaceuticals, Endotis, Novelix and VaxInnate.
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Novelix Pharmaceuticals Inc.
  • Senior Management
  • Burkhard Jansen, MD, Pres. & CEO
    Jeremy Teraoka, CFO
    Tim Triche, MD, PhD, CSO
  • Contact Info
  • Novelix Pharmaceuticals Inc.
    Phone: (858) 454-3245
    8008 Girard Ave.
    Ste. 330
    La Jolla, CA 92037